Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449678 | 1.00 | KDM4E (0.49) | KDM4ENPC1ALDH1A1LMNAHRH3 | |
| SCHEMBL13367 | 0.81 | NPC1 (0.66) | NPC1HRH3 | |
| SCHEMBL25565671 | 0.80 | NPC1 (0.53) | KDM4ENPC1ALDH1A1LMNAHRH3 | |
| SCHEMBL12837 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1LMNAHRH3MAOB | |
| SCHEMBL12449655 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1LMNAHRH3MAOB | |
| SCHEMBL12449658 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1LMNAHRH3MAOB | |
| SCHEMBL25571582 | 0.77 | NPC1 (0.64) | KDM4ENPC1ALDH1A1HRH3HRH1 | |
| SCHEMBL24922066 | 0.77 | NPC1 (0.46) | NPC1HRH3HRH1 | |
| SCHEMBL18912343 | 0.75 | NPC1 (0.56) | NPC1HRH3 | |
| SCHEMBL15101577 | 0.74 | HRH3 (0.65) | KDM4EALDH1A1HRH3MAOBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | KDM4E 1093/4885NPC1 2123/4885ALDH1A1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.